102 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
Development Research -
- Final agreement reached with FDA on study design and analysis approach for Phase 3 safety study of IV tramadol –
Miami, FL … also advanced IV tramadol, reaching final agreement with the U.S. Food and Drug Administration (FDA) on the safety study and statistical analysis
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
is enrolled approximately 25 patients, randomly assigned to AJ201 (600mg/day) or placebo. The primary endpoint of the study is to assess safety … with the FDA on the Phase 3 safety study protocol and statistical analysis approach, including the primary endpoint. The final non-inferiority study is designed
8-K
EX-99.1
y1ecdm8z tn98qdm
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-10.2
36vxqp37y4qpdh454kf
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
k3cywq
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
7kvyi2217cp7b 4g
5 Oct 23
Free writing prospectus
5:05pm
FWP
kxg lfltwo3
3 Oct 23
Free writing prospectus
5:47pm
8-K
88a9lmjih 0i2
27 Sep 23
Other Events
4:03pm
8-K
EX-99.1
m3g50292bme7fl2 xk
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
424B3
wrmlhldw
28 Jun 23
Prospectus supplement
4:56pm